Recent Company News

• 08:41 AM ET Jul 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:12 AM ET Jul 08, 2026
  

  Hikma Pharmaceuticals launches Diazepam Injection, USP in the US (1634.0000p, -27)

• 06:51 AM ET Jul 08, 2026
  

  StreetAccount Summary - European unusual volume traders

• 05:28 AM ET Jun 18, 2026
  

  Celltrion notes part 1 approval for European Phase 3 Clinical Trial Plan for CT-P13 SC has expired (KRW 173600.0000, 0)

• 05:38 PM ET Jun 04, 2026
  

  Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

• 10:08 AM ET Jun 04, 2026
  

  Supreme Court rules in Hikma Pharmaceuticals v. Amarin Pharma; reverses and remands Federal Circuit decision, holding that Amarin has failed to state a claim for active patent infringement

• 07:07 AM ET Jun 04, 2026
  

  Hikma Pharmaceuticals a publié son Rapport de durabilité 2025 (1441.0000p, +25)

• 07:07 AM ET Jun 04, 2026
  

  Hikma Pharmaceuticals published its 2025 Sustainability Report (1441.0000p, +25)

• 03:14 PM ET Jun 03, 2026
  

  Hikma Pharmaceuticals announces launch of Tofacitinib oral solution in US (1416.0000p, 0)